Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) on May 21, 2025, reporting events occurring on May 15 and May 16, 2025. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and the terms of a new employment agreement.
Material Changes
- Resignation of CFO: Michelle Yanez resigned as Chief Financial Officer, Treasurer, and Secretary effective May 16, 2025. The separation was mutual and not based on any disagreement with the Company.
- Appointment of New CFO: Alan Weichselbaum was appointed Chief Financial Officer effective May 15, 2025, with an employment start date of May 19, 2025.
- Compensation Structure: Mr. Weichselbaum's employment agreement includes an annual salary of $60,000 and an option grant of up to 50,000 shares of Common Stock.
- Vesting Schedule: The stock options vest in two tranches: 25,000 options after six months and 25,000 options after twelve months, contingent on continued employment.
Outlook, Risks, and Management Commentary
Management highlights Mr. Weichselbaum's over 30 years of experience in corporate finance, capital markets, and strategic advisory. His background includes roles as a CFO for MIRA Pharmaceuticals, Inc., a director at FinWise Bancorp, and founder of The Wexus Group. The Company intends to leverage his expertise in investor relations, capital formation, and M&A to advance financial and strategic objectives. The employment is on an at-will basis, allowing termination by either party at any time.
Key Facts for Investor Verification
- Verify the exact vesting conditions and exercise price of the 50,000 stock options granted to the new CFO.
- Confirm the transition timeline between the resignation of Michelle Yanez and the start date of Alan Weichselbaum.
- Review the full text of the Employment Agreement (Exhibit 10.1) for any additional compensation clauses or severance terms not detailed in the summary.
- Assess the impact of the CFO change on the Company's ongoing drug development and capital raising strategies.